Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure.

Literature DB >> 24804757

Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure.

Robert F Siliciano¹.

Abstract

Mesh：

Substances：
AIDS Vaccines

Year: 2014 PMID： 24804757 DOI： 10.1038/nm.3550

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

15 in total

1. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors: D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal: Nat Med Date: 1999-05 Impact factor: 53.440

Review 2. The challenge of finding a cure for HIV infection.

Authors: Douglas D Richman; David M Margolis; Martin Delaney; Warner C Greene; Daria Hazuda; Roger J Pomerantz
Journal: Science Date: 2009-03-06 Impact factor: 47.728

3. Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors: Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal: N Engl J Med Date: 2013-10-23 Impact factor: 91.245

4. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors: Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245

5. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.

Authors: Scott G Hansen; Jonah B Sacha; Colette M Hughes; Julia C Ford; Benjamin J Burwitz; Isabel Scholz; Roxanne M Gilbride; Matthew S Lewis; Awbrey N Gilliam; Abigail B Ventura; Daniel Malouli; Guangwu Xu; Rebecca Richards; Nathan Whizin; Jason S Reed; Katherine B Hammond; Miranda Fischer; John M Turner; Alfred W Legasse; Michael K Axthelm; Paul T Edlefsen; Jay A Nelson; Jeffrey D Lifson; Klaus Früh; Louis J Picker
Journal: Science Date: 2013-05-24 Impact factor: 47.728

Review 6. The implications of viral reservoirs on the elite control of HIV-1 infection.

Authors: Robert W Buckheit; Maria Salgado; Karen O Martins; Joel N Blankson
Journal: Cell Mol Life Sci Date: 2012-08-04 Impact factor: 9.261

7. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors: T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal: Proc Natl Acad Sci U S A Date: 1998-07-21 Impact factor: 11.205

8. A quantitative basis for antiretroviral therapy for HIV-1 infection.

Authors: Benjamin L Jilek; Melissa Zarr; Maame E Sampah; S Alireza Rabi; Cynthia K Bullen; Jun Lai; Lin Shen; Robert F Siliciano
Journal: Nat Med Date: 2012-02-19 Impact factor: 53.440

9. Immune clearance of highly pathogenic SIV infection.

Authors: Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal: Nature Date: 2013-09-11 Impact factor: 49.962

10. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors: Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal: N Engl J Med Date: 2014-01-16 Impact factor: 91.245

14 in total

1. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.

Authors: Rachna Aneja; Antonella Grigoletto; Aakansha Nangarlia; Adel A Rashad; Steven Wrenn; Jeffrey M Jacobson; Gianfranco Pasut; Irwin Chaiken
Journal: J Pept Sci Date: 2019-02-27 Impact factor: 1.905

2. Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent.

Authors: Ashok Chauhan
Journal: Microbes Infect Date: 2015-06-02 Impact factor: 2.700

3. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.

Authors: Rachna Aneja; Adel A Rashad; Huiyuan Li; Ramalingam Venkat Kalyana Sundaram; Caitlin Duffy; Lauren D Bailey; Irwin Chaiken
Journal: J Med Chem Date: 2015-04-28 Impact factor: 7.446

Review 4. Finding a helix in a haystack: nucleic acid cytometry with droplet microfluidics.

Authors: Iain C Clark; Adam R Abate
Journal: Lab Chip Date: 2017-06-13 Impact factor: 6.799

5. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors: Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal: J Clin Invest Date: 2016-12-12 Impact factor: 14.808

Review 6. Immunologic strategies for HIV-1 remission and eradication.

Authors: Dan H Barouch; Steven G Deeks
Journal: Science Date: 2014-07-11 Impact factor: 47.728

7. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.

Authors: Alek M Aranyos; Shannon R Roff; Ruiyu Pu; Jennifer L Owen; James K Coleman; Janet K Yamamoto
Journal: Vaccine Date: 2016-01-21 Impact factor: 3.641